Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

LILLY-PORTUGAL PRODUTOS FARMACÊUTICOS LDA

NIF 500165602
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €5,973,771 39 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €5,973,771 39 contracts
A2 · Late Publication €163,120,899,724 1,974 contracts
Contract published to BASE more than 10 days after the signing date
LOW €163,120,899,724 1,974 contracts
A5 · Threshold Splitting €9,174,335 74 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €9,174,335 74 contracts
A6 · Low Competition €2,517,511 29 contracts
Only one bidder participated in a competitive procedure
MEDIUM €2,517,511 29 contracts
A9 · Price Overrun €87,496 3 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
HIGH €48,172 1 contracts
MEDIUM €39,324 2 contracts
A9 · Abnormal Price Reduction €166,650,922,544 973 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €166,650,922,544 973 contracts
B5 · Benford's Law Deviation €147,456,136,800 1 contracts
Entity's contract values deviate from the Benford leading-digit distribution (chi-square goodness-of-fit, min 20 contracts). Score: 35 (p<0.05) or 55 (p<0.01).
MEDIUM €147,456,136,800 1 contracts
C3 · Missing Mandatory Fields €2,344,688 41 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €2,344,688 41 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

48
€148,111,495,210
320
€3,143,255,591
37
€640,580,803
174
€616,647,934
131
€610,415,497
49
€598,113,865
21
€596,211,790
90
€596,055,636
118
€576,152,448
28
€568,112,332
48
€557,656,688
274
€555,949,159
9
€555,906,932
29
€545,268,445
19
€538,158,250
8
€535,170,486
39
€520,053,551
14
€511,618,075
16
€507,406,114
27
€494,885,385
Page 1 of 4 · 62 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Price Overrun A9 · Abnormal Price Reduction B5 · Benford's Law Deviation C3 · Missing Mandatory Fields

Page 1 of 1 · 3 contracts

Aquisição Medicamento RAMUCIRUMAB 10MG/ML;50ML;SOL INJ;FRS
PT · 9429748 · Ao abrigo de acordo-qu...
A9 · Price Overrun
€17,324 2022-08-26
MEDICAMENTOS
PT · 7828815 · Ajuste Direto Regime G...
A9 · Price Overrun
€48,172 2021-08-31
FEXC0064/2018-IXECIZUMAB 80MG/ML CANETA SOL INJ
PT · 4456616 · Ajuste Direto Regime G...
A9 · Price Overrun A2 · Late Publication
€22,000 2018-03-26
Overview
Total Value Won
€166,749,658,566
Contracts Won
2,781
Score 94800 · CRITICAL RISK
NIF
500165602
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • A.D. [P-4240]
    Gerente
    since 2024-02-12
  • J.E. [P-675a]
    Gerente
    since 2012-12-28
  • J.E. [P-675a]
    Gerente
    since 2018-02-05
  • J.C. [P-aa14]
    Gerente
    since 2026-01-30
  • D.P. [P-a798]
    Sócio
    since 2008-06-25
  • E.L. [P-4640]
    Sócio
    since 2008-06-25
  • A.L. [P-40e8]
    Gerente
    2016-12-02 → 2024-02-12
  • C.B. [P-3a7c]
    Gerente
    2024-11-22 → 2026-01-30
  • E.G. [P-a9c9]
    Gerente
    2008-11-05 → 2012-03-20
  • L.E. [P-5eeb]
    Gerente
    2024-04-19 → 2024-11-22
  • N.D. [P-c99e]
    Gerente
    2018-02-05 → 2024-04-19
  • P.L. [P-166e]
    Gerente
    2012-03-20 → 2012-12-28
  • V.R. [P-7bf5]
    Gerente
    until 2016-12-02
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned